Waldenstrom Macroglobulinemia - Pipeline Review, H1 2016

  • ID: 3720447
  • Drug Pipelines
  • 214 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AbbVie Inc.
  • arGEN-X BV
  • BeiGene, Ltd.
  • Genentech, Inc.
  • IGF Oncology, LLC.
  • Juno Therapeutics Inc.
  • MORE
Waldenstrom Macroglobulinemia - Pipeline Review, H1 2016

Summary

‘Waldenstrom Macroglobulinemia - Pipeline Review, H1 2016’, provides an overview of the Waldenstrom Macroglobulinemia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Waldenstrom Macroglobulinemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Waldenstrom Macroglobulinemia and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Waldenstrom Macroglobulinemia
- The report reviews pipeline therapeutics for Waldenstrom Macroglobulinemia by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Waldenstrom Macroglobulinemia therapeutics and enlists all their major and minor projects
- The report assesses Waldenstrom Macroglobulinemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Waldenstrom Macroglobulinemia

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Waldenstrom Macroglobulinemia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Waldenstrom Macroglobulinemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie Inc.
  • arGEN-X BV
  • BeiGene, Ltd.
  • Genentech, Inc.
  • IGF Oncology, LLC.
  • Juno Therapeutics Inc.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Waldenstrom Macroglobulinemia Overview

Therapeutics Development

Pipeline Products for Waldenstrom Macroglobulinemia – Overview

Waldenstrom Macroglobulinemia – Therapeutics under Development by Companies

Waldenstrom Macroglobulinemia – Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Waldenstrom Macroglobulinemia – Products under Development by Companies

Waldenstrom Macroglobulinemia – Companies Involved in Therapeutics Development

AbbVie Inc.

Amgen Inc.

arGEN-X BV

Aurigene Discovery Technologies Limited

Bayer AG

BeiGene, Ltd.

Calithera Biosciences, Inc.

Celgene Corporation

Genentech, Inc.

Gilead Sciences, Inc.

Hutchison MediPharma Limited

Idera Pharmaceuticals, Inc.

IGF Oncology, LLC.

Incyte Corporation

Juno Therapeutics Inc.

Karyopharm Therapeutics, Inc.

Merck KGaA

Millennium Pharmaceuticals, Inc.

Novartis AG

Takeda Pharmaceutical Company Limited

Vivolux AB

Waldenstrom Macroglobulinemia – Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Combination Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

(INCB-039110 + INCB-040093) - Drug Profile

Product Description

Mechanism of Action

R&D Progress

765IGF-MTX - Drug Profile

Product Description

Mechanism of Action

R&D Progress

acalabrutinib - Drug Profile

Product Description

Mechanism of Action

R&D Progress

alisertib - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ARGX-110 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

BGB-3111 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

bortezomib - Drug Profile

Product Description

Mechanism of Action

R&D Progress

CA-4948 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

carfilzomib - Drug Profile

Product Description

Mechanism of Action

R&D Progress

CB-839 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

copanlisib hydrochloride - Drug Profile

Product Description

Mechanism of Action

R&D Progress

DI-B4 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

entospletinib - Drug Profile

Product Description

Mechanism of Action

R&D Progress

everolimus - Drug Profile

Product Description

Mechanism of Action

R&D Progress

HMPL-523 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

IMO-8400 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

INCB-40093 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

INCB-50465 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

itacitinib adipate - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ixazomib citrate - Drug Profile

Product Description

Mechanism of Action

R&D Progress

JCAR-015 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

lenalidomide - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ofatumumab - Drug Profile

Product Description

Mechanism of Action

R&D Progress

oprozomib - Drug Profile

Product Description

Mechanism of Action

R&D Progress

selinexor - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecules to Inhibit IRAK4 for Immunology and Oncology - Drug Profile

Product Description

Mechanism of Action

R&D Progress

spebrutinib besylate - Drug Profile

Product Description

Mechanism of Action

R&D Progress

venetoclax - Drug Profile

Product Description

Mechanism of Action

R&D Progress

VLX-1570 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Waldenstrom Macroglobulinemia – Recent Pipeline Updates

Waldenstrom Macroglobulinemia - Dormant Projects

Waldenstrom Macroglobulinemia – Discontinued Products

Waldenstrom Macroglobulinemia – Product Development Milestones

Featured News & Press Releases

May 27, 2015: Amgen To present data from Oprozomib study at the 20th Congress of the EHA

Nov 07, 2013: Amgen and Onyx Pharmaceuticals Announce Upcoming Data Presentations On Oprozomib at 55th American Society of Hematology Annual Meeting

Apr 01, 2013: Onyx Pharma To Present Data On Oprozomib At 14th International Myeloma Workshop

Nov 06, 2012: Onyx Pharma Announces Data Presentations On Oprozomib At 54th American Society Of Hematology Annual Meeting

Nov 08, 2011: Genmab To Present Data On Ofatumumab At 53rd American Society Of Hematology Annual Meeting And Exposition

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Waldenstrom Macroglobulinemia, H1 2016

Number of Products under Development by Companies, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Development, H1 2016

Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016 (Contd..1)

Waldenstrom Macroglobulinemia – Pipeline by AbbVie Inc., H1 2016

Waldenstrom Macroglobulinemia – Pipeline by Amgen Inc., H1 2016

Waldenstrom Macroglobulinemia – Pipeline by arGEN-X BV, H1 2016

Waldenstrom Macroglobulinemia – Pipeline by Aurigene Discovery Technologies Limited, H1 2016

Waldenstrom Macroglobulinemia – Pipeline by Bayer AG, H1 2016

Waldenstrom Macroglobulinemia – Pipeline by BeiGene, Ltd., H1 2016

Waldenstrom Macroglobulinemia – Pipeline by Calithera Biosciences, Inc., H1 2016

Waldenstrom Macroglobulinemia – Pipeline by Celgene Corporation, H1 2016

Waldenstrom Macroglobulinemia – Pipeline by Genentech, Inc., H1 2016

Waldenstrom Macroglobulinemia – Pipeline by Gilead Sciences, Inc., H1 2016

Waldenstrom Macroglobulinemia – Pipeline by Hutchison MediPharma Limited, H1 2016

Waldenstrom Macroglobulinemia – Pipeline by Idera Pharmaceuticals, Inc., H1 2016

Waldenstrom Macroglobulinemia – Pipeline by IGF Oncology, LLC., H1 2016

Waldenstrom Macroglobulinemia – Pipeline by Incyte Corporation, H1 2016

Waldenstrom Macroglobulinemia – Pipeline by Juno Therapeutics Inc., H1 2016

Waldenstrom Macroglobulinemia – Pipeline by Karyopharm Therapeutics, Inc., H1 2016

Waldenstrom Macroglobulinemia – Pipeline by Merck KGaA, H1 2016

Waldenstrom Macroglobulinemia – Pipeline by Millennium Pharmaceuticals, Inc., H1 2016

Waldenstrom Macroglobulinemia – Pipeline by Novartis AG, H1 2016

Waldenstrom Macroglobulinemia – Pipeline by Takeda Pharmaceutical Company Limited, H1 2016

Waldenstrom Macroglobulinemia – Pipeline by Vivolux AB, H1 2016

Assessment by Monotherapy Products, H1 2016

Assessment by Combination Products, H1 2016

Number of Products by Stage and Target, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Waldenstrom Macroglobulinemia Therapeutics – Recent Pipeline Updates, H1 2016

Waldenstrom Macroglobulinemia – Dormant Projects, H1 2016

Waldenstrom Macroglobulinemia – Discontinued Products, H1 2016

List of Figures

Number of Products under Development for Waldenstrom Macroglobulinemia, H1 2016

Number of Products under Development by Companies, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Top 10 Targets, H1 2016

Number of Products by Stage and Top 10 Targets, H1 2016

Number of Products by Top 10 Mechanism of Actions, H1 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Types, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
AbbVie Inc.
Amgen Inc.
arGEN-X BV
Aurigene Discovery Technologies Limited
Bayer AG
BeiGene, Ltd.
Calithera Biosciences, Inc.
Celgene Corporation
Genentech, Inc.
Gilead Sciences, Inc.
Hutchison MediPharma Limited
Idera Pharmaceuticals, Inc.
IGF Oncology, LLC.
Incyte Corporation
Juno Therapeutics Inc.
Karyopharm Therapeutics, Inc.
Merck KGaA
Millennium Pharmaceuticals, Inc.
Novartis AG
Takeda Pharmaceutical Company Limited
Vivolux AB
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll